Q-omics provides the consensus-scored COX18 profile across patient tissues and cancer cell-line models. COX18 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, COX18 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, COX18 RNA expression shows 19,151 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, BLCA, and UVM as cancer lineages where COX18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX18 survival associations across molecular data types. COX18 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX18 RNA expression–survival associations across cancer types. High COX18 expression shows unfavorable associations in UVM and HNSC, but favorable associations in COAD, KIRP, UCEC and ACC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for COX18 RNA expression.
This table summarizes COX18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for COX18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX18 shows lower tumor expression in KIRC and higher tumor expression in BLCA, LUAD, COAD, STAD and BRCA. The BLCA box plot shows higher COX18 RNA expression in tumor versus normal tissue (log2 FC = +0.573, t-test p = .002).
This table shows molecular features associated with COX18 in patient tissues and cancer cell lines. In patient samples, COX18 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
